Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 11/20 | 0.76 |
| ▸ | MAPK9 | P45984 | 10/20 | 0.76 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.37 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3740598 | 0.90 | MAPK10 (0.85) | MAPK10MAPK9MAPK8MEN1KMT2A | |
| SCHEMBL15920592 | 0.90 | MAPK9 (0.61) | MAPK10MAPK9MAPK8MEN1KMT2A | |
| SCHEMBL3748955 | 0.90 | MAPK10 (0.81) | MAPK10MAPK9MAPK8MEN1KMT2A | |
| SCHEMBL3746727 | 0.88 | MAPK10 (0.79) | MAPK10MAPK9MAPK8MEN1KMT2A | |
| SCHEMBL4200034 | 0.88 | MAPK10 (0.84) | MAPK10MAPK9MAPK8LTA4HKCNH2 | |
| Bentamapimod SCHEMBL2878382 | 0.86 | MAPK10 (1.00) | MAPK10MAPK9MAPK8MEN1KMT2A | |
| Bentamapimod SCHEMBL29350260 | 0.86 | MAPK10 (1.00) | MAPK10MAPK9MAPK8MEN1KMT2A | |
| Bentamapimod SCHEMBL29423429 | 0.86 | MAPK10 (1.00) | MAPK10MAPK9MAPK8MEN1KMT2A | |
| Bentamapimod SCHEMBL30197744 | 0.86 | MAPK10 (1.00) | MAPK10MAPK9MAPK8MEN1KMT2A | |
| SCHEMBL4198021 | 0.86 | MAPK10 (0.81) | MAPK10MAPK9MAPK8MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8592414-B2 | JNK inhibitors for the treatment of endometriosis | Merck Serono, S.A. (CH) | 2013-11-26 | — | — | US | claimed |
| US-20100121057-A1 | Process for the Preparation of Piperazine Benzothiazoles | MERCK SERONO SA (CH) | 2010-05-13 | — | — | US | claimed |
| US-7314878-B2 | Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or CNS disorders | LABORATORIES SERONO SA (CH) | 2008-01-01 | — | — | US | claimed |
| EP-1696909-B1 | BENZOTHIAZOLE DERIVATIVES FOR THE TREATMENT OF DIABETES | SERONO LAB (CH) | 2007-11-14 | — | — | EP | claimed |
| US-20070088017-A1 | Benzothiazole derivatives for the treatment of diabetes | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-04-19 | — | — | US | claimed |
| US-20050261304-A1 | Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or cns disorders | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-11-24 | — | — | US | claimed |
| US-7838522-B2 | Benzothiazole formulations and use thereof | ARES TRADING S.A. (CH) | 2010-11-23 | — | — | US | disclosed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
| US-20100121057-A1 | Process for the Preparation of Piperazine Benzothiazoles | MERCK SERONO SA (CH) | 2010-05-13 | — | — | US | disclosed |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
| EP-2137173-A2 | PROCESS FOR THE PREPARATION OF PIPERAZINE BENZOTHIAZOLES | Laboratoires Serono SA (CH) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008125518-A2 | PROCESS FOR THE PREPARATION OF PIPERAZINE BENZOTHIAZOLES | MERCK SERONO S.A. (CH) | 2008-10-23 | — | — | WO | disclosed |
| US-20080051397-A1 | Benzothiazole Formulations and Use Thereof | ARES TRADING S.A. (CH) | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | MAPK10 338/4885MAPK9 185/4885MAPK8 275/4885 |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | PDK1, PDK2, PDK3 | MAPK10 202/4885MAPK9 232/4885MAPK8 284/4885 |
| US-20080051397-A1 | Benzothiazole Formulations and Use Thereof | MGLL, MBOAT4, MBOAT1 | MAPK10 3176/4885MAPK9 3960/4885MAPK8 4361/4885 |
| US-20070088017-A1 | Benzothiazole derivatives for the treatment of diabetes | GPR119, GLS2, GLS | MAPK10 3255/4885MAPK9 4264/4885MAPK8 3132/4885 |
| US-20050261304-A1 | Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or cns disorders | PRDX5, PIR, GRIK5 | MAPK10 3536/4885MAPK9 4329/4885MAPK8 3901/4885 |
| US-20100121057-A1 | Process for the Preparation of Piperazine Benzothiazoles | NUDT1, BRD1, BRD4 | MAPK10 3620/4885MAPK9 3286/4885MAPK8 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.